New Treatment Strategy for Gastric Cancer That Has Spread to the Peritoneum
- 18 hours ago
- 2 min read
Associations between the primary colorectal tumor budding score and the histological growth pattern of peritoneal metastases: A pilot study. Bouatrous, Mendhi et al. Surgical Oncology Insight, Volume 3, Issue 1, 100236.
About This Research
Gastric (stomach) cancer that spreads to the lining of the abdomen—called peritoneal carcinomatosis—is one of the most difficult forms of the disease to treat. Traditional chemotherapy given through the bloodstream often struggles to reach cancer cells in the peritoneal cavity effectively, which contributes to poor outcomes for many patients.
A recent study published in Surgical Oncology Insight highlights a promising treatment strategy that combines systemic chemotherapy with chemotherapy delivered directly into the abdomen, potentially improving outcomes for patients with gastric cancer that has spread to the peritoneum.
Why This Research Matters
Peritoneal metastasis occurs in a significant proportion of patients with advanced gastric cancer and is associated with very limited survival—often only a few months with standard treatment. Researchers are exploring ways to deliver treatment more directly to the affected area to improve disease control and extend survival.
The Approach: Combining Systemic and Intraperitoneal Chemotherapy
The study focuses on a treatment strategy similar to the approach used in the STOP-GAP clinical trial, which uses a sequential, multimodal approach:
Initial systemic chemotherapy: Patients first receive several months of standard chemotherapy through the bloodstream to control disease throughout the body.
Intraperitoneal chemotherapy: If the disease has not progressed, chemotherapy—often paclitaxel—is delivered directly into the abdominal cavity through a small implanted port. This allows higher concentrations of the drug to reach tumors on the peritoneal surfaces.
Reassessment and possible surgery: After treatment, patients are evaluated with imaging and laparoscopy to measure the extent of disease.
Patients whose tumors respond well and have low-volume disease may become eligible for cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC), which aims to remove visible cancer and destroy remaining microscopic cells.
Key Findings
The research suggests that this combined regional and systemic treatment approach is feasible and promising for patients with gastric peritoneal carcinomatosis.
Important observations include:
The strategy was tolerable and feasible for most patients.
Delivering chemotherapy directly into the abdomen may improve drug delivery to tumors in the peritoneum, which systemic chemotherapy alone often cannot achieve.
Some patients experienced enough tumor response to become eligible for potentially life-extending surgery and HIPEC, which is rarely possible with standard treatment alone.
What This Means for Patients
While the approach is still being studied, the findings support the idea that multimodal therapy—combining systemic treatment, intraperitoneal chemotherapy, and surgery in selected patients—may improve outcomes for this difficult-to-treat disease.
Researchers emphasize that larger, multi-center clinical trials are needed to confirm the benefits of this strategy and determine which patients are most likely to benefit.
Looking Ahead
This research represents an important step toward more personalized and targeted treatment for patients with gastric cancer that spreads to the peritoneum. If confirmed in larger studies, this approach could help redefine treatment options and offer new hope for patients facing this aggressive form of cancer.
